This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Sickle Cell Disease > Dosing and Administration
Print

In this section:

EU SmPC
Sickle Cell Disease Dosing and Administration

Dose-dependent Reductions in Liver Iron Concentration Demonstrated at 1 Year1

EXJADE Delivers Dose-dependent
Reductions in Liver Iron Concentration1
Change in Liver Iron Concentration

Data from a 1-year, open-label phase II trial, evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean + SD) in LIC determined according to assigned treatment category for EXJADE.1

Titrate and monitor to reach chelation goals2

  • Monitor serum ferritin monthly and assess trends with steady-state levels
  • Titrate EXJADE by steps of 5 mg/kg/day to 10 mg/kg/day as early as 3 months based on individual patient’s response and therapeutic goals (maintenance or reduction of iron)
  • The recommended daily starting dose of EXJADE is 20 mg/kg body weight
  • EXJADE is approved at doses up to 40 mg/kg/day for patients not adequately controlled with doses of 30 mg/kg (eg, serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time)
  • Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level
  • Dose reductions, in steps of 5 to 10 mg/kg, should be considered in patients whose serum ferritin levels have reached the target (usually between 500 and 1000 µg/L) in order to maintain serum ferritin levels within the target range

Learn more about monitoring

EXJADE DOSING OPTIONS

Titrate from the recommended starting
dose of 20 mg/kg/day based on
individual patient’s response and therapeutic goals. Please check the Prescribing Information for your region
for details.

Learn more

EXJADE ADMINISTRATION

Help ensure your patients
properly take their once-daily
oral therapy.

Learn more

References

  1. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
  2. EXJADE® summary of product characteristics. West Sussex, United Kingdom: Novartis Europharm Limited; 2011.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed